myTomorrows, a healthcare technology company that helps patients access treatments before formal approval, announced it has raised $29 million in funding from Avego. This investment will support the global growth of myTomorrows’ integrated pharma platform and help make experimental therapies more accessible and equitable for patients around the world.
Health Technology Insights: WebMD Ignite Launches Pulse to Help Health Systems Thrive in an AI Efficiency-First Era
With over 300 million patients globally living with conditions that currently lack approved treatments and more than 10,000 therapies under development or awaiting approval, myTomorrows is addressing a critical gap in healthcare. The platform connects patients, physicians, clinical trial sites, and pharmaceutical companies, enabling faster access to treatments through clinical trials and expanded access programs while streamlining data collection and regulatory insights.
Health Technology Insights: Amigo Establishes Medical Advisory Board and Appoints Dr. Jay Shah as Chief Medical Advisor
The funding will accelerate international expansion and enhance myTomorrows’ AI-powered platform. This includes improving treatment matching, trial referrals, and access management while strengthening partnerships with BioPharma to reduce clinical development timelines and increase real-world evidence generation. Michel van Harten, CEO of myTomorrows, said the investment is a significant step toward ensuring patients worldwide can access emerging therapies fairly. He emphasized that Avego’s expertise in life sciences will be critical to scaling the platform and expanding its global impact.
James Flexner, Managing Partner at Avego, highlighted the company’s commitment to supporting myTomorrows’ mission to remove barriers for patients and physicians while acting as a reliable partner to BioPharma. Ronald Brus, Founder and Board Member of myTomorrows, reflected on the company’s founding vision in 2012 to create a system that connects patients to promising therapies and said the investment marks a new phase of accelerated growth and international reach.
Currently, myTomorrows offers the most extensive AI-driven platform for pre-approval therapies, supporting more than 16,900 patients in over 133 countries. The platform helps patients and doctors navigate treatment options, gain access to clinical trials and expanded access programs, and provides BioPharma partners with clinical trial recruitment, real-world data collection, and expanded access solutions. By connecting all stakeholders, myTomorrows is creating a global infrastructure for pre-approval therapies, empowering patients and enabling timely access to innovative treatments.
Health Technology Insights: Ceipal Enhances Ceipal Healthcare To Deliver Faster Staffing Solutions
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
